Biotech

Versartis Reports First Quarter 2018 Financial Results

Biotech

Versartis (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018. As quoted in the press release: For the first quarter ended March 31, 2018, Versartis reported a net loss of approximately $9.0 million, or $0.25 per share, basic and diluted, compared to a net loss for the first …

Versartis (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018.

As quoted in the press release:

For the first quarter ended March 31, 2018, Versartis reported a net loss of approximately $9.0 million, or $0.25 per share, basic and diluted, compared to a net loss for the first quarter ended March 31, 2017 of $29.7 million, or $0.85 per share, basic and diluted.

Total operating expenses for the quarter ended March 31, 2018 were $8.5 million compared to $29.7 million for the quarter ended March 31, 2017. Research and development (R&D) expenses for the quarter ended March 31, 2018 were $3.6 million, compared to $22.0 million for the quarter ended March 31, 2017. The decrease in R&D expenses was primarily due to the termination of clinical and manufacturing related contracts that supported the company’s Phase 3 clinical trials for somavaratan following the Phase 3 VELOCITY trial failing to meet its primary endpoint.

Click here to read the full press release.

MARKETS

Markets
TSX20767.38+195.27
TSXV626.17+8.58
DOW34086.04+368.95
S&P 5004076.60+58.83
NASD11584.55+190.74
ASX7481.70-12.10

COMMODITIES

Commodities
Gold1928.03+5.93
Silver23.69+0.11
Copper4.22-0.01
Palladium1713.170.00
Platinum1087.260.00
Oil79.03+0.16
Heating Oil3.140.00
Natural Gas2.73+0.05

DOWNLOAD FREE REPORTS

×